Name: Latest research reports of Laurus Labs Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

831.5000 9.65 (1.17%)

NSE Aug 11, 2025 15:51 PM

99.07% Gain from 52W Low

Volume: 1.3M

Laurus Labs Ltd.

27 Jan 2025

831.50

1.17%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. has gained 32.75% in the last 6 Months